Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™.
VIDEO | Meet The Board | CEO & MD, Paul Anderson
The first episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring CEO & MD, Paul Anderson.
Launching October 2024 | Meet The Board
As part of a special ‘Meet the Board’ video series launching in October 2024, we are pleased to bring you face to face with the team at the top. Tune in for inspiring insights into their vision for our Company.
Ausbiz | Interview with John Van Der Wielen
Orthocell Chairman, John Van Der Wielen spoke with ausbiz host Nadine Blayney about the Company’s expansion into Canada with dental bone regeneration product, Striate+, and Orthocell’s strong outlook for revenue growth.
Proactive | Interview with John Van Der Wielen
Following the Company’s announcement last week confirming the first sales of Striate+ in Canada, Orthocell’s Chairman John Van Der Wielen spoke with Proactive’s Tylah Tully about the Company’s swift transition from regulatory approval to sales in the Canadian market, and plans to expand into the Singapore and Brazil markets within the next six to 12 months.
The Australian | Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada
Orthocell’s entry to to the Canadian market with the first sales of Striate+ has been reported in The Australian in the article “Orthocell’s collagen-membrane dental-regeneration product Striate+ debuts in Canada”.
First Sales of Striate+™ in New and Significant Market of Canada
Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+™ in the key market of Canada.
Petra Capital Research Report | September 2024
Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share.
The report summarises Orthocell’s revenue growth, and the strong outlook for the Company as it expands its global footprint with regulatory applications either planned or in progress for Remplir and Striate+.
The author noted:
“FY24 saw OCC’s Remplir and Striate products continue to gain traction after ~18 months on market. OCC is now focused on expanding the global footprint of both products. It is targeting 7 new markets, while continuing to execute on growing revenues from existing markets and progressing partnering process for Remplir and non-core tendon cell therapy (with the appointment of US advisors). A renewed Board and strong cash position are supporting this effort. We reiterate BUY, with our $1.28/sh TP offering >3x upside.”
Orthocell submits Singapore Regulatory Application for Striate+™
Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+™ in Singapore, has been accepted for review by Health Services Authority of Singapore (HSA).
Proactive | Interview with Paul Anderson
Following the announcement that Orthocell is accelerating its global market expansion of Striate+™ and Remplir™, Managing Director Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s seven regulatory applications in progress or planned, targeting approval in significant markets.
Paul spoke of the positive feedback from clinicians on Orthocell’s innovative regenerative medicine products and plans to capture a meaningful share of the global market as part of the Company’s growth strategy.
“Orthocell has always focused on providing solutions for clinicians. When you combine those that are available to us, from both our dental bone product and our nerve product, we’re talking about $3 billion a year in addressable markets. We’re very confident, given the outstanding uptake that we’ve seen for both Striate+ and Remplir, that we can drive towards a 20% market share of that market. And we think that we can do that with our partners, in conjunction with the excellent product and education that we provide to surgeons internationally.”